Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 4, 1999, Pages 341-349

  Irie, Akira ^a   Anderegg, Birgit ^a   Kashani Sabet, Mohammed ^b   Ohkawa, Tsukasa ^a   Suzuki, Toshiya ^a   Halks Miller, Meredith ^a   Curiel, David T ^c   Scanlon, Kevin J ^a  

^a BAYER AG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOZYME;

ADENOVIRUS; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; TUMOR REGRESSION; VIRUS RECOMBINANT;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 0032817549     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1999.9.341     Document Type: Article

References (15)

1. BARBACID, M. (1987). ras genes. Annu. Rev. Biochem. 56, 779-827.
2. BASS, C. CABRERA, G., ELGAVISH, A., ROBERT, B., SIEGAL, G.P., ANDERSON, S.C., MANEVAL, D.C., and CURIEL, D.T. (1995). Recombinant adenovirus-mediated gene transfer to geni-tourinaiy epithelium in vitro and in vivo. Cancer Gene Ther. 2, 97-104.
3. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
4. BOS, J.L. (1989). ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689.
5. CAMERON, F.H., and JENNINGS, P.A. (1989). Specific gene suppression by engineered ribozymes in monkey cells. Proc. Natl. Acad. Sci. USA 86, 9139-9143.
6. CUSACK, J.C., SPITZ, F.R., NGUYEN, D., ZHANG, W.-W., CRISTIANO, R.J., and ROTH, J.A. (1996). High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus. Cancer Gene Ther. 3, 245-249.
7. CZUBAYKO, F., DOWNING, S.G., HSIEH, S.S., GOLDSTEIN, D.J., LU, P.Y., TRAPNELL, B.C., and WELLSTEIN, A. (1997). Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. 4, 943-949.
8. FENG, M., CABRERA, G., DESHANE, J., SCANLON, K.J., and CURIEL, D.T. (1995). Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 55, 2024-2028.
9. FUNATO, T., SHITARA, T., TONE, T., JIAO, L., KASHANI-SABET, M., and SCANLON, K.J. (1994). Suppression of H-ras mediated transformation of NIH 3T3 by a H-ras ribozyme. Biochem. Pharmacol. 48, 1471-1475.
10. GREIG, R.G., KOESTLER, T.P., TRAINER, D.L., CORWIN, S.P., MILES, L., KLINE, T., SWEET, R., YOKOYAMA, S., and POSTE, G. (1985). Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells. Proc. Natl. Acad. Sci. USA 82, 3698-3701.
11. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A., Mc-CORMICK, F., VON HOFF, D.D., and KIRN. D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639-645.
12. HOMANN, M., TZORTZAKAKI, S., RITTNER, K., SCZALIEL, G., and TABLER, M. (1993). Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1. Nucleic Acids Res. 21, 2809-2814.
13. IRIE, A., BOUFFARD, D.Y., and SCANLON, K.J. (1997). Ribozyme-mediated cancer gene therapy. Int. J. Urol. 4, 329-337.
14. IRIE, A., TSAI, J., and KASHANI-SABET, M. (1998). Adenoviral-mediated anti-Hras ribozyme for the treatment of bladder cancer. In: Therapeutic Application of Ribozymes. K.J. Scanlon, ed. (Humana Press, Totowa, NJ), pp. 153-168.
15. KASHANI-SABET, M., FUNATO, T., FLORENES, V.A., FODSTAD, O., and SCANLON, K.J. (1994). Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54, 900-902.